Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 USD | -1.89% | -0.48% | -37.54% |
May. 13 | Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating | MT |
May. 09 | Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.54% | 243M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- CHRS Stock
- News Coherus BioSciences, Inc.
- Coherus BioSciences to Sell Cemerli Ophthalmology Business to Sandoz for $170 Million